FMP
Acacia Pharma Group plc
ACPH.BR
BRU
Inactive Equity
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
0.888 EUR
0 (0%)
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
